Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Postmenopausal women with metastatic, hormone receptor-positive breast cancer may now be treated with everolimus (Afinitor) in combination with exemestane (Aromasin), following FDA’s recent approval of the tablet medicine.
FDA approves pertuzumab (Perjeta) for use in treating HER2 positive metastatic breast cancer when combined with trastuzumab (Herceptin), an anti-HER2 medicine that targets a different part of the HER2 protein, and docetaxel (Taxotere), a type ofchemotherapy.
HONG KONG (Reuters) - Breast cancer cells can shut down a powerful immune response in the body, which allows the disease to spread to the patient's bones, researchers in Australia reported on Monday.
(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Novartis AG's drug Afinitor to treat women with a certain type of breast cancer.
CHICAGO (Reuters) - A study of Roche's experimental "armed antibody" found it extended the length of time breast cancer patients lived without their disease getting worse, marking the second successful pivotal trial in this new class of cancer drugs.
(Reuters) - A pair of newer drugs proved no better, and by some measures inferior, to the older and cheaper chemotherapy agent paclitaxel in patients with locally advanced or metastatic breast cancer, according to results of a late stage study.
(Reuters) - Interim results from a mid-stage trial of Celldex Therapeutics Inc's experimental drug showed trends toward reducing tumors in patients with advanced breast cancer, with rates improving for those patients with high levels of a key protein.
Learn how new research has prompted the American Society of Clinical Onclolgy (ASCO) to recommend that doctors offer palliative care alongside standard medical treatment for people diagnosed with metastatic cancers.
(Reuters) - AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.